Traditionally, erythropoiesis-stimulating agents (ESAs) such as recombinant human erythropoietin (rEPO) alfa (epoetin alfa; Eprex®) have been employed to treat anaemia in various conditions such as chronic kidney disease (CKD) and chemotherapy-induced anaemia [4]. This evidence concerns the gene EPO and anemia (phenotype).